Autopsy report · NCT02719990

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

“Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 36 participants enrolled.
• Results were posted on the registry 5 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Versartis Inc.

Sponsor type

Industry

Conditions

Adult Growth Hormone Deficiency (AGHD)

Interventions

somavaratan

Participants

36

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.